Showing results (51-60 of 272) with videos related to

Sort By:
Pageof 28
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Challenges in Opening and Enrolling Patients in Clinical TrialsJulie M Vose, Meredith K Chuk, Francis Giles
Cancer|January 28, 2004
New agents in acute myeloid leukemia and other myeloid disordersFarhad Ravandi, Hagop Kantarjian, Francis Giles, et al.
Expert Opinion on Pharmacotherapy|May 22, 2013
Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?Ciara Freeman, Niamh Keane, Ronan Swords, et al.
Cancer Journal (Sudbury, Mass.)|November 23, 2007
Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatmentElias Jabbour, Jorge Cortes, Francis Giles, et al.
European Journal of Haematology|September 30, 2020
Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti-tumor activity in multiple myelomaKatie R Ryan, Francis Giles, Gareth J Morgan
Future Oncology (London, England)|June 4, 2008
Current status of therapy for chronic myeloid leukemia: a review of drug developmentSwami Padmanabhan, Saritha Ravella, Tyler Curiel, et al.
Investigational New Drugs|August 6, 2022
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumorsXiaofei Zhou, Ulka Vaishampayan, Devalingam Mahalingam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2019
Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor ActivityDevalingam Mahalingam, Judy S Wang, Erika P Hamilton, et al.
Current Drug Targets|July 23, 2011
Targeting TRAIL towards the clinicDevalingam Mahalingam, Corina N A M Oldenhuis, Eva Szegezdi, et al.
Cancers|July 15, 2026
KRAS Subtype Modifies Outcomes with Immunomodulatory Therapy in Advanced Pancreatic Ductal Adenocarcinoma: Evidence from Early-Phase TrialsDilsa Mizrak Kaya, Yangruijue Ma, Tarik Demir, et al.
Pageof 28